NRx Pharma Starts Mid-Stage COVID-19 Vaccine Trial In Nation of Georgia

NRx Pharmaceuticals Inc NRXP has initiated a phase 2b dose-confirmatory trial of the BriLife vaccine against COVID-19 in the Nation of Georgia.
The vaccine is developed by the Israel Institute for Biological Research (IIBR).
The purpose of the study is to confirm the vaccine's ability to generate an immune response against the COVID-19 Delta variant before entering phase 3 trials in multiple nations.
The phase 2b program will also incorporate a potential intradermal vaccination option. A small quantity of vaccine will be placed into the skin instead of a traditional needle injection into a muscle.
The clinical trials in Georgia will take place simultaneously as the completion of the second phase of clinical trials in Israel.
In July, NRx Pharma's intravenous Zyesami (aviptadil) to treat critical COVID-19 patients received Emergency Use Authorization in the Nation of Georgia.
Price Action: NRXP shares are up 12.90% at $15.51 during the market session on the last check Monday.